Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04589468 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04589468 · ClinicalTrials.gov record · last posted 2026-08-27

Researching the Effect of Exercise on Cancer

StatusRecruiting
PhaseNot applicable
Started2026-10-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA levels) will be found. Each level of exercise tested will be a certain number of minutes each week. Once the best level of exercise is found, it will be tested further in a new group of participants. All participants in this study will have been previously treated for breast, prostate, or colorectal cancer.

Protocol amendment history 6 changes detected by DataLookout

2026-08-28
notable
Enrollment reopened
2026-08-28
notable
Enrollment increased: 33 → 51 participants
2026-08-28
critical
Primary completion pushed: 2026-10-02 → 2028-02-13
2026-08-28
minor
Completion pushed: 2026-12-20 → 2028-02-13
2026-07-25
notable
Sponsor changed: Memorial Sloan Kettering Cancer Center → City of Hope Medical Center
WasMemorial Sloan Kettering Cancer Center
NowCity of Hope Medical Center
2026-07-25
minor
Completion pushed: 2026-10-02 → 2026-12-20
Trial Details
NCT Number NCT04589468
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer, Prostate Cancer, Colorectal Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer +4 more
Enrollment 51 participants
Start Date 2026-10-30
Primary Completion 2028-02-13 (estimated)
Study Completion 2028-02-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-27